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Abstract
IMPORTANCE—Agreement between patient- and practitioner-reported toxic effects during 
chemoradiotherapy for head and neck cancer is unknown.
OBJECTIVE—To compare patient-reported symptom severity and practitioner-reported toxic 
effects among patients receiving chemoradiotherapy for head and neck cancer.
DESIGN, SETTING, AND PARTICIPANTS—Forty-four patients participating in a phase 2 trial 
of deintensified chemoradiotherapy for oropharyngeal carcinoma were included in the present 
study (conducted from February 8, 2012, to March 2, 2015). Most treatment (radiotherapy, 60 Gy, 
with concurrent weekly administration of cisplatin, 30mg/m2) was administered at academic 
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medical centers. Included patients had no prior head and neck cancers, were 18 years or older, and 
had a smoking history of 10 pack-years or less or more than 10 pack-years but 30 pack-years or 
less and abstinent for the past 5 years. Cancer status was untreated human papillomavirus or p16-
positive squamous cell carcinoma of the oropharynx or unknown head and neck primary site; and 
cancer staging was category T0 to T3, category N0 to N2c, M0, and Eastern Cooperative 
Oncology Group performance status 0 to 1. Baseline, weekly, and posttreatment toxic effects were 
assessed by physicians or nurse practitioners using National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (CTCAE), version 4.0. Patient-reported symptom 
severity was measured using the Patient-Reported Outcomes version of the CTCAE (PRO-
CTCAE). Descriptive statistics were used to characterize raw agreement between CTCAE grades 
and PRO-CTCAE severity ratings.
INTERVENTIONS—Baseline, weekly, and posttreatment toxic effects assessed using CTCAE, 
version 4.0, and PRO-CTCAE.
MAIN OUTCOMES AND MEASURES—Raw agreement indices between patient-reported 
toxic effects, including symptom frequency, severity, and interference with daily activities (score 
range, 0 [none] to 4 [very severe]), and practitioner-measured toxic effects, including swallowing, 
oral pain, and hoarseness (score range, 1 [mild] to 5 [death]).
RESULTS—Of the 44 patients included in the analysis (39 men, 5 women; mean [SD] age, 61 
[8.4] years), there were 327 analyzable pairs of CTCAE and PRO-CTCAE symptom surveys and 
no treatment delays due to toxic effects. Patient-reported and practitioner-reported symptom 
severity agreement was high at baseline when most symptoms were absent but declined 
throughout treatment as toxic effects increased. Most disagreement was due to lower severity of 
toxic effects reported by practitioners (eg, from 45% agreement at baseline to 27% at the final 
week of treatment for pain). This was particularly noted for domains that are not easily evaluated 
by physical examination, such as anxiety and fatigue (eg, severity of fatigue decreased from 43% 
at baseline to 12% in the final week of treatment).
CONCLUSIONS AND RELEVANCE—Practitioner-reported toxic effects are lower than patient 
self-reports during head and neck chemoradiotherapy. The inclusion of patient-reported 
symptomatic toxic effects provides information that can potentially enhance clinical management 
and improve data quality in clinical trials.
Accurate assessment of toxic effects is an essential function in cancer clinical trials and 
routine care of cancer patients. In clinical trials, investigators commonly evaluate and 
quantify toxic effects and adverse events using the Common Terminology Criteria for 
Adverse Events (CTCAE) instrument developed by the National Cancer Institute.1 Emerging 
evidence suggests that direct patient reporting of symptoms may improve the accuracy and 
validity of toxic effects assessment.2 Disagreement between patient-reported and 
practitioner-reported symptomatic toxic effects has been extensively described3 and 
between-practitioner agreement in toxic effects ratings may also be only modest.4 There is 
evidence5,6 to suggest that, compared with practitioner reporting, patient-reported symptoms 
are more strongly correlated with clinical outcomes.
To improve the reliability of capturing treatment-related adverse events, the National Cancer 
Institute has developed a library of patient-reported outcome (PRO) measures that 
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complement the CTCAE. The PRO version of the CTCAE (PRO-CTCAE) allows patients to 
self-report the frequency, severity, and activity interference of symptoms that they are 
experiencing while undergoing treatment.7 Implementation of the PRO-CTCAE may 
improve the quality of adverse event data in clinical trials and foster communication 
between patients and practitioners.8 The PRO-CTCAE has demonstrated2 favorable validity, 
reliability, and responsiveness in patients undergoing cancer treatment.
The use of patient-reported measures has been recommended9 in head and neck cancer 
treatment trials. Head and neck cancers develop in tissues with close proximity to vital 
anatomical structures that are involved in important physiologic (swallowing and eating) and 
social (communication) functions; thus, the prevalence, severity, and impact of treatment-
related toxic effects is high.10 Chemoradiotherapy is a standard and intensive treatment for 
cancers of the head and neck, with approximately 50% of the patients experiencing severe to 
very severe acute and late toxic effects.10–12 Although chemoradiotherapy for head and neck 
cancer is an outpatient treatment, 20% of patients will have an unplanned hospital 
admission.13 The National Cancer Institute Symptom Management and Quality of Life 
Steering Committee conducted a clinical trials planning meeting to identify a standard core 
set of PRO symptoms to be assessed across all disease sites and in head and neck cancer 
clinical trials.14 This core set of symptoms is also included in the PRO-CTCAE item library.
We have incorporated a subset of PRO-CTCAE items to assess the National Cancer Institute 
core symptoms into our multi-institutional head and neck chemoradiotherapy trials. To our 
knowledge, there are no published data regarding the use of PRO-CTCAE (specifically, how 
PRO-CTCAE reports compare with CTCAE assessments) in head and neck clinical trials. 
The purpose of this study was to compare patient reporting (PRO-CTCAE) with practitioner 
reporting (CTCAE) of symptom severity using data derived from a multi-institutional 
clinical trial15 of chemoradiotherapy in patients with head and neck cancer.
Methods
Participants and Study Treatment
We conducted an analysis of patients enrolled in a prospective phase 2 clinical trial 
(NCT01530997).15 The primary objective of the phase 2 study was to evaluate the efficacy 
of a deintensified chemoradiotherapy regimen in favorable-risk, human papilloma virus 
(HPV)–associated oropharyngeal squamous cell carcinoma. The study, including the present 
analysis of patient- and practitioner-reported toxic effects, received institutional review 
board approval at the participating centers. All patients provided written informed consent; 
no financial compensation was provided. Enrolling institutions included the University of 
North Carolina Hospitals, Chapel Hill; University of Florida Hospitals, Gainesville; and Rex 
Hospital, Raleigh, North Carolina. The study was conducted from February 8, 2012, to 
March 2, 2015.
Eligible patients (age, ≥18 years; all native English speakers) had a smoking history of 10 
pack-years or less or more than 10 pack-years but 30 pack-years or less and had been 
abstinent for the past 5years; adequate hematologic, renal, and liver function; no prior head 
and neck cancers; and untreated, pathologically confirmed HPV- or p16-positive squamous 
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cell carcinoma of the oropharynx or from an unknown head and neck primary site that was 
category T0 to 3, category N0 to N2c, M0, and Eastern Cooperative Oncology Group 
performance status 0 to 1.
All patients received intensity-modulated radiotherapy delivered to a total dose of 60 Gy at 2 
Gy per fraction 5 days per week for 6 weeks. A dose of 54 Gy was delivered to anatomical 
regions at risk for subclinical disease. Concurrent weekly low-dose cisplatin (30 mg/m2) was 
administered, with dose modifications allowed as needed. Within 6 to 14 weeks after 
chemoradiotherapy, all patients underwent planned surgical evaluation, which consisted of a 
biopsy of the primary site and dissection of pretreatment-positive lymph node regions.15
Measurement Scales
The core set of symptoms recommended for assessment in head and neck clinical trials 
includes difficulty swallowing, oral pain, skin changes, dry mouth, lowered dental health, 
difficulty with opening mouth or trismus, impaired taste, excess or thick mucus or saliva, 
shoulder disability or impaired motion, and altered voice or hoarseness.10 Additional 
symptoms recommended for assessment across all disease sites are fatigue, insomnia, pain, 
anorexia (appetite loss), dyspnea, cognitive problems, anxiety (includes worry), nausea, 
depression (sad and unhappy feelings), sensory neuropathy, constipation, and diarrhea.14 
Dental health and shoulder disability or impaired motion are health states rather than 
symptomatic toxic effects; thus, they are not evaluated using PRO-CTCAE. Furthermore, 
symptoms such as insomnia, dyspnea, cognitive problems, and sensory neuropathy occur 
infrequently with this regimen.
Criteria for grading on the CTCAE scale vary by toxic effects; however, grade 1 typically 
refers to mild symptoms not requiring intervention, grade 2 refers to moderate symptoms 
that interfere somewhat with daily function and where some intervention may be indicated, 
and grade 3 refers to severe symptoms that interfere with daily activities or require more 
significant intervention. Grade 4 toxic effects (life-threatening, with urgent intervention 
indicated) and grade 5 (death) are indicative of significantly higher levels of toxic effects and 
are not applicable for symptomatic effects such as fatigue, tinnitus, hoarseness, or 
xerostomia. A patient-reported symptom rated as severe or very severe may not correspond 
to CTCAE grade 4 or 5 toxic effects; however, severe levels of patient-reported toxic effects 
may indicate a higher risk of impending serious adverse events.6
The PRO-CTCAE measurement system includes questions related to symptom frequency, 
severity, and interference with daily activities (none, mild, moderate, and severe/very 
severe), as well as presence/absence and amount, as relevant to the symptom under 
consideration.7
PRO-CTCAE items reflecting the 13 symptomatic toxic effects chosen for surveillance in 
this study were assessed via an online questionnaire (Qualtrics LLC). The study coordinator 
(including R.G.) provided participants with a tablet computer during scheduled weekly 
visits. PRO-CTCAE and CTCAE assessments were obtained before treatment, weekly 
during chemoradiotherapy, and at subsequent follow-up visits.
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Statistical Analysis
Practitioner-reported toxicity was graded using CTCAE from 1 (mild) to 5 (death). For 
domains in which the practitioner determined that a toxicity was not present, a grade of 0 
was assigned. No patients experienced grade 4 (life-threatening) or grade 5 (death) toxic 
effects; these grades were removed from the CTCAE assessment scale for purposes of 
comparison with PRO-CTCAE scores. Therefore, the CTCAE scores had a restricted range 
from 0 (none) to 3 (severe). Severity of symptoms using the PRO-CTCAE was scored as 
follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe), and 4 (very severe). To facilitate direct 
comparison between CTCAE and PRO-CTCAE, patient-reported symptoms rated as severe 
and very severe were classified together as severe.
The analysis reported here examines comparisons between CTCAE grades and PRO-
CTCAE symptom severity scores. For the 5 PRO-CTCAE symptom terms where a 
frequency question is asked first (pain, anxiety, depressed mood, nausea, and vomiting), if a 
patient indicated no symptom frequency, then a score of none was assigned for severity for 
the purposes of this analysis. The timing of the practitioner assessments of toxic effects was 
uniform across all institutions in this study. Assessments were made by physicians or nurse 
practitioners after weekly clinic visits without knowledge of the PRO-CTCAE reports for 
that assessment time point or prior time points.
Descriptive statistics were used to summarize the patient cohort demographics and disease 
characteristics. Results of toxic effects assessments using CTCAE and PRO-CTCAE were 
summarized at baseline and for each week of treatment. For each symptom assessment time 
point and each symptom domain, we measured the raw agreement between CTCAE grade 
and PRO-CTCAE symptom severity. We then analyzed the proportion of pairs with 
symptomatic adverse events scored or graded as more severe by patients or practitioners, as 
well as the degree of discrepancy. Agreement between practitioners and patients was defined 
as the same severity of toxic effects reported by practitioners using the CTCAE scale (grade 
0, 1, 2, or 3) and patients using the PRO-CTCAE (none, mild, moderate, and severe/very 
severe), for a given time point. To further evaluate how increasing symptom severity may 
impact differences between CTCAE grades and PRO-CTCAE severity scores, Bland-Altman 
plots were constructed for the following symptom domains: pain, dysphagia, nausea, and 
vomiting. These domains were chosen because under-ascertainment of toxic effects by 
practitioners for these symptoms could lead to adverse events, such as emergency 
department visits or unplanned hospitalization. All statistical analyses were performed using 
SAS, version 9.4 (SAS Institute Inc).
Results
There were evaluable data for 44 of 45 patients (98%) enrolled in this phase 2 clinical trial 
(Table 1). Thirty-nine patients (89%) were male and 40 patients (91%) were white. All 
patients completed the full course of radiotherapy (60 Gy), and 31 individuals (70%) 
received the planned 6 weekly doses of cisplatin. There were no radiotherapy treatment 
delays related to toxic effects. Surgical evaluation was performed for 43 patients (1 patient 
lost to follow-up did not undergo surgery) at a mean (SD) of 9 (2) weeks (range, 7–14 
weeks) after completion of radiotherapy. Seventeen patients (39%) required placement of a 
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percutaneous gastrostomy tube for a mean duration of 15 (4) weeks (range, 5–22 weeks). No 
patient required a long-term gastrostomy tube. All patients were alive with no evidence of 
disease (median follow-up, 21 months, range, 4–41 months). Thirty-eight patients (86%) had 
a follow-up of at least 1 year.
There were 352 scheduled visits at which patients were expected to self-report symptoms 
using PRO-CTCAE. Complete PRO-CTCAE data were available for 335 of those visits, 
yielding an adherence rate of 95.2%. At these same visits, practitioners submitted 342 
CTCAE reports (adherence rate, 97.2%). There were 25 instances (of 352 of planned 
assessments) where either CTCAE or PRO-CTCAE data were unavailable for comparison, 
resulting in 327 (92.9%) analyzable pairs of CTCAE and PRO-CTCAE symptom reports at 
baseline, during treatment, and 6 months after treatment for the 44 patients. Raw indices of 
agreement between practitioner-reported and patient-reported symptom severity are reported 
in Table 2. The highest agreement was noted at baseline (before treatment), with agreement 
declining throughout the course of treatment (eFigure in the Supplement). An overall 
decrease in practitioner and patient agreement was seen for every symptom domain across 
the course of treatment. For example, agreement in the severity of fatigue was 43%at 
baseline and 12% in the final week of treatment.
Toxic effects due to chemoradiotherapy are cumulative and typically are greatest at the end 
of treatment. A summary of the PRO-CTCAE scores and CTCAE grades for symptom toxic 
effects in the final week of treatment is given in Table 3. Practitioner-reported CTCAE 
grades were generally lower than PRO-CTCAE scores, especially for symptom domains not 
easily evaluable by physical examination. For example, fatigue was reported as mild by 6 
patients (14%), but practitioners reported fatigue as none or mild for 36 patients (82%). 
There was greater agreement for symptomatic toxic effects, such as radiation-associated 
dermatitis and mucositis, although a similar pattern of discrepancy between practitioner 
grades and patient severity scores was present in these domains as well.
Bland-Altman plots for pairs of CTCAE and PRO-CTCAE symptom reports for pain, 
dysphagia, nausea, and vomiting are shown in the Figure. These plots demonstrate that 
greater disagreement between practitioners and patients was observed, with practitioners 
reporting lower CTCAE grades compared with patient-reported PRO-CTCAE severity 
scores.
Discussion
The present study reports a direct comparison between CTCAE grades and PRO-CTCAE 
scores for patients-with head and neck cancer who are receiving chemoradiotherapy. 
Although there is apparent similarity between grading scales for PRO-CTCAE and CTCAE, 
differences between CTCAE grades and PRO-CTCAE scores should not be overinterpreted. 
Disagreement between PRO-CTCAE and CTCAE toxic effects assessment may not 
represent under-ascertainment by practitioners or overreporting by patients. For example, a 
patient may meet criteria for grade 1 vomiting by CTCAE criteria (1 or 2 episodes separated 
by 5minutes in a 24-hour period), but to the patient, 2 daily episodes of vomiting constitutes 
a severe symptom. Frequent management of severe toxic effects by practitioners may skew 
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practitioners’ perceptions of symptom severity. The severity of chemoradiotherapy-
associated toxic effects represents a potential source of discordance between practitioner-
reported and patient-reported symptoms (eg, daily vomiting alone not categorized as a high-
grade toxic effect by the practitioner, but considered quite severe by the patient). There is no 
objective standard for a correct ascertainment of symptom severity. The lack of an objective 
standard supports the goal of collecting as much information as possible regarding 
symptoms from both patients and practitioners to obtain the most complete and accurate 
picture of toxic effects.
A substantial percentage of the disagreement between practitioner- and patient-reported 
symptoms reflected disagreement by 1 point. The clinical impact of these small differences 
likely depends on the domain being assessed as well as the extent of symptom severity. A 
disagreement between mild fatigue and no fatigue is not likely to affect clinical management 
or patient outcomes, but a difference between moderate dysphagia and severe dysphagia 
could have potentially significant implications regarding patient nutrition or the possible 
need for aggressive intervention, such as gastric tube placement. In the present study, it was 
not possible to directly evaluate the association between discordant ratings and patient 
outcomes because there were few severe adverse events (eg, unplanned hospitalization, 
placement of feeding tube, and death) in this sample of patients receiving a deintensified 
regimen of chemoradiotherapy for oropharyngeal cancer.
There are unique challenges when attempting to directly compare CTCAE and PRO-
CTCAE data. These scoring instruments were not developed for direct comparison, but 
rather were designed to be complementary strategies for capturing symptomatic adverse 
events. A limitation of the present study is the relatively low number of practitioner 
assessors of toxic effects. However, CTCAE grades are defined by explicit criteria, which 
should promote uniformity in toxic effects grading by different assessors.
Both PRO-CTCAE and CTCAE measurement systems evaluate symptomatic toxic effects 
relative to symptom severity, frequency, and interference with activities. In addition, CTCAE 
grading criteria incorporate the need for clinical intervention. Depending on the symptom 
under consideration, all 3 factors may be assessed in the PRO-CTCAE and CTCAE scales, 
which can complicate efforts to make comparisons. For example, in the evaluation of 
vomiting, frequency and severity are assessed by PRO-CTCAE, whereas frequency and the 
need for clinical intervention are reflected in CTCAE grading criteria. As a consequence, the 
present analysis compared PRO-CTCAE vomiting severity with CTCAE vomiting grade.
The direct comparison between CTCAE and PRO-CTCAE in this study serves to highlight 
patient perceptions regarding their symptoms due to head and neck cancer. For example, 
more than 30% of the patients reported some degree of xerostomia and/or mucositis at 
baseline. These symptoms are not readily attributable to untreated oropharyngeal cancer. 
Similarly, a high degree of hoarseness was reported at baseline and increased throughout 
treatment. Patients in this trial did not have laryngeal involvement with cancer, and the 
radiation dose to the larynx was minimized during radiotherapy planning. This finding 
suggests that it may be difficult for patients to precisely localize their symptoms when 
communicating with practitioners.
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In the present study, practitioner assessments of toxic effects were made without knowledge 
of patient-reported symptoms. As PRO-CTCAE continues to be incorporated into clinical 
practice, there is an obvious benefit in systematically providing practitioners with patient-
reported data, which may contribute to their assessment of toxic effects. Furthermore, 
weekly or other periodic assessment of PRO-CTCAE may be supplemented by a real-time 
symptom monitoring approach. The use of Internet and mobile devices that allow patients to 
report symptoms as they occur could provide additional insight into the timing and severity 
of symptoms.16–18
Chemoradiotherapy-associated toxic effects that developed in treatment of head and neck 
cancer reported in this study may be lower owing to the dose reduction used in the 
deintensified regimen. In addition, studies19,20 suggest that patients with non–HPV-
associated head and neck cancer may experience worse symptoms compared with patients 
with HPV-associated tumors. It is unclear what effect tumor HPV status may have on 
agreement between patient- and practitioner-reported toxic effects. The patients in this study 
were participants in a phase 2 clinical trial at institutions with dedicated head and neck 
cancer teams, and the level of supportive care provided to patients was similar at all 
institutions. Studies21–24 have shown improved oncologic outcomes for patients with head 
and neck cancer treated with multimodality therapy at high-volume centers compared with 
lower-volume centers. Findings from this study may not apply to patients with 
oropharyngeal cancer treated in community centers.
Conclusions
The severity of symptoms ascertained by practitioners was lower than that reported by 
patients, and these differences increased throughout a course of chemoradiotherapy for 
oropharyngeal cancer. The clinical implications of these differences are unknown. The 
inclusion of patient-reported data helps to provide a more complete picture of toxic effects 
that patients experience during cancer treatment.
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Key Points
Question
How do patient-reported symptoms compare with practitioner-reported toxic effects 
among patients receiving chemoradiotherapy for head and neck cancer?
Findings
Agreement between patients and practitioners was high at baseline but decreased 
throughout the course of treatment. Most of the disagreement involved lower severity of 
the toxic effects reported by practitioners.
Meaning
The inclusion of patient-reported data helps to provide a more accurate and complete 
picture of toxic effects that patients experience during cancer treatment.
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Figure. Common Terminology Criteria for Adverse Events (CTAE) and the Patient-Reported 
Outcomes Version of the CTCAE (PRO-CTCAE) Symptom Survey Pairs for Pain, Dysphagia, 
Nausea, and Vomiting
Differences noted in reports on pain (A), dysphagia (B), nausea (C), and vomiting (D) are 
plotted against the mean of the PRO-CTCAE score (score range, 0 [none] to 4 [very severe]) 
and the CTCAE grade (score range, 1 [mild] to 5 [death]) from 327 survey pairs. The large 
bubble point (position 0, 0) for all symptoms indicates a high level of agreement between 
patients and practitioners when toxic effects are absent. As the toxic effects increase (x-
axis), the number of agreements between patients and practitioners diminishes, as 
demonstrated by the decreasing size of the bubbles and their greater distance from the x-
axis. Bubble points lying directly on the x-axis indicate that patient-reported severity tended 
to be greater than the corresponding toxic effect grade provided by the practitioner.
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Table 1
Characteristics of 44 Patients
Characteristic No. (%)a
Age, mean (SD) [range] 61 (8.4)[44–76]
Sex
  Male 39 (89)
  Female 5 (11)
Race
  African American 4 (9)
  White 40 (91)
Marital status
  Married 34 (77)
  Unmarried 10 (23)
Tobacco use
  Never 36 (82)
  ≤10 Pack-years 6 (14)
  >10 Pack-years 2 (5)
Primary tumor location
  Tonsil 16 (36)
  Base of tongue 26 (59)
  Unknown 2 (5)
T category
  T0 2 (5)
  T1 13 (30)
  T2 22 (50)
  T3 7 (16)
N category
  N0 4 (9)
  N1 10 (23)
  N2a 2 (5)
  N2b 21 (48)
  N2c 7 (16)
HPV/p16 status
  HPV+/p16+ 28 (64)
  HPV−/p16+ 16 (36)
Treatment site
  University of North Carolina 30 (68)
  University of Florida 12 (27)
  Rex Hospital 2 (5)
Abbreviation: HPV, human papilloma virus.
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a
Percentages may not equal 100% because of rounding.
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